Publications by authors named "A S Jobert"
Most transplant-ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti-CD38 monoclonal antibody at first relapse and represent a difficult-to-treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.
View Article and Find Full Text PDFBackground: After idiopathic epiretinal membrane (iERM) removal, it is unclear whether the internal limiting membrane (ILM) should be removed. The objective was to assess if active ILM peeling after iERM removal could induce microscotomas.
Methods: The PEELING study is a national randomised clinical trial.
High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM), and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant-eligible (TE) NDMM. HR cytogenetics were defined by presence of del(17p), t(4;14), and/or t(14;16).
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed XAV-19, an antibody treatment, for hospitalized COVID-19 patients with severe symptoms, focusing on its safety and effectiveness in preventing death or serious respiratory failure.
- - Conducted across 34 hospitals in France, the trial involved 398 adult patients who were randomly assigned to receive either XAV-19 or a placebo, with no major differences in outcomes observed between the two groups after 15 days.
- - Findings revealed that treatment with XAV-19 did not lead to a significant reduction in the incidence of severe health complications compared to placebo, and adverse events were similarly reported in both groups.
Purpose: We aimed to determine whether interferon gamma-1b prevents hospital-acquired pneumonia in mechanically ventilated patients.
Methods: In a multicenter, placebo-controlled, randomized trial conducted in 11 European hospitals, we randomly assigned critically ill adults, with one or more acute organ failures, under mechanical ventilation to receive interferon gamma-1b (100 µg every 48 h from day 1 to 9) or placebo (following the same regimen). The primary outcome was a composite of hospital-acquired pneumonia or all-cause mortality on day 28.